文献速递细菌感染、耐药与抗菌药物

静脉用来法莫林治疗急性细菌性皮肤及皮肤结构感染的靶标达成率

Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

研究基于群体药代动力学模型和蒙特卡洛模拟,评估静脉用来法莫林治疗急性细菌性皮肤及皮肤结构感染的靶标达成率。针对抑菌靶标,CABP获批剂量150 mg q12h对MSSA和MRSA的总体靶标达成率分别为94%和84%,100 mg q12h方案则降至68%和50%。针对1-log杀菌靶标,两种方案的总体靶标达成率均低于40%。

要点

  • 150 mg q12h对MSSA和MRSA的抑菌靶标达成率分别为94%和84%。
  • 100 mg q12h对MSSA和MRSA的抑菌靶标达成率分别为68%和50%。
  • 两种方案对1-log杀菌靶标的总体达成率均低于40%。

核心结论

  • 来法莫林现行静脉获批剂量以抑菌暴露为目标时覆盖大多数金黄色葡萄球菌分离株,提示其治疗ABSSSI的潜力。
  • 当需要快速杀菌活性时,来法莫林可能不适用于ABSSSI。

研究设计与样本

  • 采用ABSSSI患者来法莫林的群体药代动力学模型进行蒙特卡洛模拟,计算不同剂量的PTA。
  • 结合临床前抑菌和细菌计数1-log降低的暴露靶标,并利用来法莫林MIC分布计算对MSSA和MRSA的总体靶标达成率。

主要发现

  • 对CABP获批的静脉剂量150 mg q12h,抑菌靶标的总体达成率对MSSA为94%,对MRSA为84%。
  • 100 mg q12h方案对MSSA的抑菌靶标总体达成率为68%,对MRSA为50%。
  • 采用1-log降低靶标时,两种方案的总体靶标达成率均低于40%。

关键数值与推荐

  • 抑菌靶标:150 mg q12h对MSSA总体达成率94%,对MRSA 84%;100 mg q12h对MSSA 68%,对MRSA 50%。
  • 1-log降低靶标:150 mg q12h和100 mg q12h两种方案的总体达成率均低于40%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Lefamulin is a pleuromutilin antibiotic approved for the treatment of community-acquired bacterial pneumonia (CABP). Its spectrum of activity, good penetration into soft tissues and low rates of cross-resistance also make lefamulin a potentially valuable option for treatment of acute bacterial skin and skin structure infections (ABSSSIs). A Phase 2 trial of lefamulin for ABSSSI indicated similar efficacy of 100 and 150 mg q12h IV dosing regimens. In the present study, the potential of lefamulin for this indication was further evaluated from a translational pharmacokinetic/pharmacodynamic perspective. METHODS: PTA was determined for various dosages using Monte Carlo simulations of a population pharmacokinetic model of lefamulin in ABSSSI patients and preclinical exposure targets associated with bacteriostasis and a 1-log reduction in bacterial count. Overall target attainment against MSSA and MRSA was calculated using lefamulin MIC distributions. RESULTS: Overall attainment of the bacteriostasis target was 94% against MSSA and 84% against MRSA for the IV dosage approved for CABP (150 mg q12h). Using the same target, for the 100 mg q12h regimen, overall target attainment dropped to 68% against MSSA and 50% against MRSA. Using the 1-log reduction target, overall target attainment for both regimens was <40%. CONCLUSIONS: Lefamulin at the currently approved IV dosage covers most Staphylococcus aureus isolates when targeting drug exposure associated with bacteriostasis, suggesting potential of lefamulin for the treatment of ABSSSIs. Lefamulin may not be appropriate in ABSSSI when rapid bactericidal activity is warranted.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. van Os W, Zeitlinger M. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections. J Antimicrob Chemother. 2024. PMID: 38174805. doi:10.1093/jac/dkad401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。